多瑞醫藥(301075.SZ):擬6000萬元增資湖北天濟 佔投後5.66%
格隆匯11月16日丨多瑞醫藥(301075.SZ)公佈,為促進公司完善中醫藥整體產業佈局,提升核心競爭力,公司擬與湖北天濟藥業有限公司(簡稱“湖北天濟”或“標的公司”)簽訂《湖北天濟藥業有限公司增資協議》。
參考近期市場交易價格,並經雙方友好協商,確定增資前標的公司估值為10億元。該次公司以自有或自籌資金對湖北天濟增資6000萬元,對應註冊資本1800萬元,其餘計入資本公積,該次增資完成後佔註冊資本比例為5.66%。
公司表示,該次增資湖北天濟主要基於其在中藥飲片、藥品配送、中藥飲片製劑生產等方面具備更加完善的產業佈局,更有利於公司落實發展戰略。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.